A Phase 4 interventional study of Ibuprofen and celecoxib in Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 33 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing celecoxib in Osteoarthritis, Knee — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis, Knee.
Among the 14 studies testing celecoxib in Osteoarthritis, Knee, this one is the 3rd largest by enrollment, is one of 2 that started in 2002, is one of 10 in phase 4, and was the 5th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →1 of the 14 studies testing celecoxib in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 41+
By country, each count listing its studies:
Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 393 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 216 across the 14 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 8 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 7 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing celecoxib in Osteoarthritis, Knee, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ibuprofen
Drug: celecoxib
Other: placebo
Change from baseline in patient's assessment of arthritis pain according to visual analogue scale (VAS)
Time frame: Week 6
Vital signs
Time frame: Weeks 2 and 6
Physical examination
Time frame: Week 6
Laboratory test results
Time frame: Week 6
Adverse events
Time frame: Weeks 2 and 6
Change from baseline in patient's and physician's global assessment of pain
Time frame: Weeks 2 and 6
Pain Satisfaction Scale
Time frame: Days 1-7
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index
Time frame: Week 6
Patient Health Questionnaire (PHQ-9)
Time frame: Week 6
Change from baseline in patient's assessment of arthritis pain according to VAS
Time frame: Week 2
The record gives a start of Oct 2002, a primary completion of Mar 2003 and a completion of Mar 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibuprofen · Celecoxib
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →